Application of biophysics to the early developability assessment of therapeutic candidates and its application to enhance developability properties

Biophysics for Therapeutic Protein Development

Volumn , Issue , 2013, Pages 127-146

  Sathish, Hasige ^a   Angell, Nicolas ^b   Lowe, David ^c   Shah, Ambarish ^a   Bishop, Steven ^a  

^a MEDIMMUNE   (United States)

^b AMGEN INC   (United States)

^c MEDIMMUNE LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896502272     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4316-2_6     Document Type: Chapter

References (71)

1. Ackerman MJ, Clapham DE (1997) Ion channels-basic science and clinical disease. N Engl J Med 336(22):1575-1586.
2. Adams CP, Brantner VV (2010) Spending on new drug development1. Health Econ 19(2):130-141.
3. Anandakumar R, Harn NR, Sathish HA, LeachWL, Oliver CN, Bishop SM (2008) American Association of Pharmaceutical Scientist, National Biotech Conference, 2008.
4. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25(2):705-708.
5. Bajaj H, Sharma VK, Kalonia DS (2007) A high-throughput method for detection of protein selfassociation and second virial coefficient using size-exclusion chromatography through simultaneous measurement of concentration and scattered light intensity. Pharm Res 24(11):2071-2083.
6. Batista FD, Neuberger MS (1998) Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 8(6):751-759.
7. Bee JS, Stevenson JL, Mehta B, Svitel J, Pollastrini J, Platz R, Freund E, Carpenter JF, Randolph TW (2009) Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng 103(5):936-943.
8. Bekard IB, Asimakis P, Bertolini J, Dunstan DE (2011) The effects of shear flow on protein structure and function. Biopolymers 95(11):733-745.
9. Biddlecombe JG, Craig AV, Zhang H, Uddin S, Mulot S, Fish BC, Bracewell DG (2007) Determining antibody stability: creation of solid-liquid interfacial effects within a high shear environment. Biotechnol Prog 23(5):1218-1222.
10. Boder ET, Midelfort KS, Wittrup KD (2000) Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA 97(20):10701-10705.
11. Carter PJ (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 317(9):1261-1269.
12. Cellmer T, Bratko D, Prausnitz JM, Blanch HW (2007) Protein aggregation in silico. Trends Biotechnol 25(6):254-261.
13. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10(5):301-316.
14. Chari R, Jerath K, Badkar AV, Kalonia DS (2009) Long- and short-range electrostatic interactions affect the rheology of highly concentrated antibody solutions. Pharm Res 26(12):2607-2618.
15. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL (2009a) Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 106(29):11937-11942.
16. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL (2009b) Aggregation-prone motifs in human immunoglobulin G. J Mol Biol 391(2):404-413.
17. Chi EY, Krishnan S, Randolph TW, Carpenter JF (2003a) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20(9):1325-1336.
18. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW (2003b) Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 12(5):903-913.
19. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H (2006a) Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 177(2):1129-1138.
20. Dall'Acqua WF, Kiener PA, Wu H (2006b) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281(33):23514-23524.
21. DiMasi JA, Grabowski HG (2007) The cost of biopharmaceutical R&D: is biotech different? Manag Decis Econ 28(4-5):469-479.
22. Famm K, Hansen L, Christ D, Winter G (2008) Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol 376(4):926-931.
23. Finch DK, Sleeman MA, Moisan J, Ferraro F, Botterell S, Campbell J, Cochrane D, Cruwys S, England E, Lane S, Rendall E, Sinha M, Walker C, Rees G, Bowen MA, Schneider A, Liang M, Faggioni R, Fung M, Mallinder PR, Wilkinson T, Kolbeck R, Vaughan T, Lowe DC (2011) Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol 411(4):791-807.
24. Foote J, Eisen HN (1995) Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci USA 92(5):1254-1256.
25. Fowler SB, Poon S, Muff R, Chiti F, Dobson CM, Zurdo J (2005) Rational design of aggregationresistant bioactive peptides: reengineering human calcitonin. Proc Natl Acad Sci USA 102(29):10105-10110.
26. Gebauer M, Skerra A (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13(3):245-255.
27. George A, Wilson WW (1994) Predicting protein crystallization from a dilute solution property. Acta Crystallogr D Biol Crystallogr 50(Pt 4):361-365.
28. Goldberg DS, Bishop SM, Shah AU, Sathish HA (2011) Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques:role of conformational and colloidal stability. J Pharm Sci 100:1306-1315.
29. Hageman MJ (2006) Solubility, solubilization and dissolution in drug delivery during lead optimization. Springer, New York.
30. He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI (2010) High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem 399(1):141-143.
31. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K (2011) Engineering the variable region of therapeutic IgG antibodies. MAbs 3(3):243-252.
32. Jespers L, Schon O, Famm K, Winter G (2004) Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 22(9):1161-1165.
33. Johnson DH, Parupudi A, Wilson WW, DeLucas LJ (2009) High-throughput self-interaction chromatography:applications in protein formulation prediction. Pharm Res 26(2):296-305.
34. Karlsson M, Ekeroth J, Elwing H, Carlsson U (2005) Reduction of irreversible protein adsorption on solid surfaces by protein engineering for increased stability. J Biol Chem 280(27):25558-25564.
35. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL (2011) Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 6(1):38-44.
36. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711-715.
37. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P (2003) Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325(5):979-989.
38. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N (2009) Engineered therapeutic antibodies with improved effector functions. Cancer Sci 100(9):1566-1572.
39. Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL (2012) Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 101(1):102-115.
40. Le Brun V, Friess W, Bassarab S, Muhlau S, Garidel P (2010) A critical evaluation of self- interaction chromatography as a predictive tool for the assessment of protein-protein interactions in protein formulation development: a case study of a therapeutic monoclonal antibody. Eur J Pharm Biopharm 75(1):16-25.
41. Liu J, Nguyen MD, Andya JD, Shire SJ (2005) Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94(9):1928-1940.
42. Lundstrom K (2005) Structural genomics of GPCRs. Trends Biotechnol 23(2):103-108.
43. Ma P, Zemmel R (2002) Value of novelty? Nat Rev Drug Discov 1(8):571-572.
44. Mehta CM, White ET, Litster JD (2012) Correlation of second virial coefficient with solubility for proteins in salt solutions. Biotechnol Prog 28(1):163-170.
45. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R (2000) The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 37(12-13):697-706.
46. Minton AP (2005) Influence of macromolecular crowding upon the stability and state of association of proteins: predictions and observations. J Pharm Sci 94(8):1668-1675.
47. Naylor J, Beech DJ (2009) Extracellular ion channel inhibitor antibodies. Open Drug Discov J 1:36-42.
48. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10):767-774.
49. Norde W (1986) Adsorption of proteins from solution at the solid-liquid interface. Adv Colloid Interface Sci 25(4):267-340.
50. Oganesyan V, Damschroder MM, Leach W, Wu H, Dall'Acqua WF (2008) Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol 45(7):1872-1882.
51. Payne RW, Nayar R, Tarantino R, Del Terzo S, Moschera J, Di J, Heilman D, Bray B, Manning MC, Henry CS (2006) Second virial coefficient determination of a therapeutic peptide by selfinteraction chromatography. Biopolymers 84(5):527-533.
52. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, Eldredge J, Capili A, Mi S, Graff C, Garber E (2010) Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 19(5):954-966.
53. Prassler J, Thiel S, Pracht C, Polzer A, Peters S, Bauer M, Norenberg S, Stark Y, Kolln J, Popp A, Urlinger S, Enzelberger M (2011) HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol 413(1):261-278.
54. Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20(4):460-470.
55. Remmele RL Jr, Nightlinger NS, Srinivasan S, Gombotz WR (1998) Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm Res 15(2):200-208.
56. Salinas BA, Sathish HA, Bishop SM, Harn N, Carpenter JF, Randolph TW (2010) Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci 99(1):82-93.
57. Saluja A, Kalonia DS (2008) Nature and consequences of protein-protein interactions in high protein concentration solutions. Int J Pharm 358(1-2):1-15.
58. Scherer TM, Liu J, Shire SJ, Minton AP (2010) Intermolecular interactions of IgG1 monoclonal antibodies at high concentrations characterized by light scattering. J Phys Chem B 114(40):12948-12957.
59. Sethuraman A, Belfort G (2005) Protein structural perturbation and aggregation on homogeneous surfaces. Biophys J 88(2):1322-1333.
60. Sinha S, Zhang L, Duan S, Williams TD, Vlasak J, Ionescu R, Topp EM (2009) Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody. Protein Sci 18(8):1573-1584.
61. Stewart R, Thom G, Levens M, Guler-Gane G, Holgate R, Rudd PM, Webster C, Jermutus L, Lund J (2011) A variant human IgG1-Fc mediates improved ADCC. Protein Eng Des Sel 24(9):671-678.
62. Sule SV, Sukumar M, Weiss WF, Marcelino-Cruz AM, Sample T, Tessier PM (2011) Highthroughput analysis of concentration-dependent antibody self-association. Biophys J 101(7):1749-1757.
63. Tadros T (2011) Interparticle interactions in concentrated suspensions and their bulk (rheological) properties. Adv Colloid Interface Sci 168(1-2):263-277.
64. Tessier PM, Jinkoji J, Cheng YC, Prentice JL, Lenhoff AM (2008) Self-interaction nanoparticle spectroscopy: a nanoparticle-based protein interaction assay. J Am Chem Soc 130(10):3106-3112.
65. Thomas CR, Geer D (2011) Effects of shear on proteins in solution. Biotechnol Lett 33(3):443-456.
66. Valente JJ, Payne RW, Manning MC, Wilson WW, Henry CS (2005) Colloidal behavior of proteins:effects of the second virial coefficient on solubility, crystallization and aggregation of proteins in aqueous solution. Curr Pharm Biotechnol 6(6):427-436.
67. Vlasak J, Ionescu R (2011) Fragmentation of monoclonal antibodies. MAbs 3(3):253-263.
68. Wendorf JR, Radke CJ, Blanch HW (2004) Reduced protein adsorption at solid interfaces by sugar excipients. Biotechnol Bioeng 87(5):565-573.
69. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940-3947.
70. Yadav S, Scherer TM, Shire SJ, Kalonia DS (2011) Use of dynamic light scattering to determine second virial coefficient in a semidilute concentration regime. Anal Biochem 411(2):292-296.
71. Yadav S, Shire SJ, Kalonia DS (2012) Viscosity behavior of high-concentration monoclonal antibody solutions: correlation with interaction parameter and electroviscous effects. J Pharm Sci 101(3):998-1011.